88E
0.002
100%
OB1
0.001
-50%
BUY
0.004
100%
H2G
0.003
-25%
CR9
0.004
100%
WYX
0.03
-23.1%
AYT
0.005
66.7%
SLH
1.54
-22.2%
WOA
0.026
62.5%
IMI
0.011
-21.4%
ASR
0.003
50%
RML
0.011
-21.4%
SCP
0.19
46.2%
NAE
0.004
-20%
VAR
0.009
28.6%
RNX
0.004
-20%
BCC
0.099
25.3%
HE8
0.013
-18.8%
ADG
0.005
25%
BCB
0.005
-16.7%
MVL
0.01
25%
EPM
0.005
-16.7%
WSR
0.01
25%
HOR
0.015
-16.7%
ETM
0.087
22.5%
REC
0.015
-16.7%
FAL
0.12
21.2%
WC1
0.015
-16.7%
AKN
0.006
20%
CHR
0.042
-16%
YAR
0.006
20%
CYM
0.017
-15%
MHK
0.425
19.7%
GEN
0.034
-15%
MAUCA
1.2
19.4%
CVR
0.175
-14.6%
BSX
0.074
19.4%
IPB
0.006
-14.3%
VMC
0.11
18.3%
PWN
0.012
-14.3%

PainChek (ASX:PCK): Has progressed with FDA De Novo submission

PainChek (ASX:PCK), developer of the world’s first smart phone-based pain assessment and monitoring application, has provided an update on its progress with FDA de Novo submission for the PainChek Adult App.

– Majority of requirements for submission complete – Clinical Evaluation Report in final stages
– PainChek expects to provide a further update this month regarding the submission
– US Aged Care market is the world’s largest – 1.7 million people long-term aged care
– Potential FDA clearance for the Adult app would be a major milestone for the Company and provides a predicate for PainChek’s use with infants and in other market segments

Philip Daffas, CEO of PainChek, said “The US Aged Care market is the largest in the world where 1,700,000 people reside in these long-term care facilities, with a potential gross annual recurring revenue value of around $85,000,000 USD for PainChek based on our projected US pricing.”

Read the ASX announcement: https://www.painchek.com/wp-content/uploads/2024/10/2787320.pdf $PCK